The 19th February 2016, Difass International obtained patent n. 1420997 entitled “Composizioni antidislipidemiche e loro uso” that will last twenty years from the application date (14th June 2013).
This is an application patent on use of DIF1STAT®, patented association of components owned by Difass International, in the treatment of dyslipidaemia in nephropathic patients suffering from Chronic Kidney Disease (CKD).
According to Difass’ R&D Director, Alida Agostini, obtaining this patent “represents the achievement of an important goal for the company, enhancing the recognition of patentend association DIF1STAT® in Italy, not only for its beneficial effect on cholesterol lowering in general population, but also in the treatment of nephropatic patients”.
Difass International is a company specialised in the design, development, formulation and sale of Nutraceuticals, Cosmetics, Medical devices and Foods for special medical purposes, offering its expertise in regulatory, productive and marketing terms. Currently Difass can rely on more than 150 people between internal staff and qualified Medical Reps, who present the products to Medical Professionals, covering almost all of the national territory, and it realises and licenses its own references also to third companies operating in the pharmaceutical industry.